University of Poitiers   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Poitiers France (1431)

Organization Overview

First Clinical Trial
1998
NCT00461825
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier Universitaire (CHU) de Poitiers | Centre Hospitalier Universitaire Poitiers | CHU 86021 Poitiers cedex | CHU de Poitiers FRANCE | CHU de Poitiers-POITIERS | CHU Poitiers | CHU POITIERS | CHU Poitiers, France | CHU POITIERS France | Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE | Department of Oncology Hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE | Dpt of Ophthalmology, University Hospital of Poitiers, France | Poitiers (FR), University College Hospital | Poitiers hospital | Poitiers Hospital University | Poitiers University | Poitiers University Hospital | Poitiers University Hospital, POITIERS, 86021, FRANCE | University College Hospital, Poitiers | University Hospital of Poitiers | University Hospital of Poitiers, france

Active Ingredients

Drugs in Phase 4 Trials (14)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

aflibercept (zaltrap) (2 trials)

albuterol (proventil) (2 trials)

cefoxitin (mefoxin) (1 trial)

chlorhexidine (hibitane) (2 trials)

cyclosporine (sandimmune) (2 trials)

ethanol (2 trials)

hypochlorite (1 trial)

imatinib (gleevec) (5 trials)

insulin aspart (novolog) (1 trial)

isopropyl alcohol (1 trial)

paroxetine (paxil) (1 trial)

povidone-iodine (4 trials)

rasagiline (azilect) (1 trial)

Drugs in Phase 3 Trials (45)

amoxicillin (1 trial)

amphotericin b (fungizone) (2 trials)

azathioprine (imuran) (1 trial)

bortezomib (velcade) (3 trials)

carboplatin (paraplatin) (2 trials)

ciprofloxacin (cipro) (3 trials)

cisatracurium (nimbex) (1 trial)

clarithromycin (biaxin) (1 trial)

clavulanate (Augmentin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cyproviron (1 trial)

cytarabine (cytosar-u) (2 trials)

daptomycin (cubicin) (1 trial)

dexamethasone (2 trials)

emtricitabine (emtriva) (1 trial)

esomeprazole (nexium) (1 trial)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (2 trials)

flutamide (eulexin) (1 trial)

hydroquinine (1 trial)

Isatuximab (Sarclisa) (2 trials)

itraconazole (sporanox) (1 trial)

lenalidomide (revlimid) (2 trials)

leuprolide (lupron) (1 trial)

medroxyprogesterone (provera) (1 trial)

melphalan (alkeran) (2 trials)

metronidazole (flagyl) (2 trials)

milrinone (primacor) (1 trial)

mycophenolate (myfortic) (2 trials)

nitrous oxide (1 trial)

oxygen (2 trials)

pegylated-interferon (1 trial)

phloroglucinol (1 trial)

prednisolone (hydeltra) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

propofol (diprivan) (1 trial)

s100b (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (1 trial)

tacrolimus (prograf) (1 trial)

tamsulosin (flomax) (1 trial)

tenofovir (viread) (1 trial)

tetracycline (tetrex) (1 trial)

urea (1 trial)

venlafaxine (effexor) (1 trial)

Drugs in Phase 2 Trials (42)

adalimumab (humira) (1 trial)

atomoxetine (strattera) (1 trial)

bevacizumab (avastin) (2 trials)

capecitabine (xeloda) (1 trial)

carfilzomib (kyprolis) (1 trial)

ceftriaxone (rocephin) (1 trial)

cetuximab (erbitux) (3 trials)

clindamycin (cleocin) (1 trial)

dasatinib (sprycel) (1 trial)

daunorubicin (cerubidine) (1 trial)

degarelix acetate (firmagon) (1 trial)

dexeryl (1 trial)

etoposide (vepesid) (1 trial)

fluoromisonidazole (1 trial)

fluoroquinolone (1 trial)

hydroxyzine (vistaril) (1 trial)

idarubicin (idamycin) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

irinotecan (Camptosar) (1 trial)

ixazomib (ninlaro) (1 trial)

lactose (1 trial)

lanreotide (somatuline depot) (1 trial)

leucovorin (1 trial)

levodopa (larodopa) (1 trial)

l-glutamine (1 trial)

lidocaine (xylocaine) (1 trial)

linezolid (zyvox) (1 trial)

mifepristone (mifeprex) (1 trial)

oxaliplatin (eloxatin) (2 trials)

pembrolizumab (keytruda) (1 trial)

pomalidomide (pomalyst) (2 trials)

pregabalin (lyrica) (1 trial)

prilocaine (citanest) (1 trial)

ranibizumab (lucentis) (1 trial)

rifampin (1 trial)

simvastatin (zocor) (1 trial)

sodium oxybate (xyrem) (1 trial)

sugammadex (bridion) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

trimethoprim (1 trial)

vancomycin (Vancocin) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (7)

acetaminophen (tylenol) (2 trials)

cefotaxime (claforan) (1 trial)

ceftaroline fosamil (teflaro) (1 trial)

colimycin (2 trials)

ertapenem (invanz) (1 trial)

fosfomycin (monurol) (1 trial)

gentamicin (garamycin) (1 trial)

Drugs in Other Trials (4)

amino acids (Freamine) (1 trial)

d12-cl2bpa (1 trial)

oxytocin (syntocinon) (1 trial)

resveratrol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Adenocarcinoma (Phase 3)

Anxiety Disorders (Phase 4)

Aspergillosis (Phase 3)

Aspergillosis, Allergic Bronchopulmonary (Phase 2)

Bacterial Infections (Phase 1)

Brain Death (Phase 4)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Brugada Syndrome (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Choroidal Neovascularization (Phase 4)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Critical Illness (Phase 3)

Cystic Fibrosis (Phase 2)

Diabetic Retinopathy (Phase 2)

Disease (Phase 4)

Disease Progression (Phase 2)

Edema (Phase 2)

Fibrosis (Phase 1)

Head and Neck Neoplasms (Phase 2)

Hemorrhage (Phase 3)

Hyperkalemia (Phase 4)

Hypoxia (Phase 2)

Infections (Phase 4)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Leiomyoma (Phase 2)

Leukemia (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)

Leukemia, Myeloid (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Macular Edema (Phase 2)

Multiple Myeloma (Phase 3)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Myofibroma (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Neovascularization, Pathologic (Phase 4)

Obesity, Morbid (Phase 2)

Pain (Phase 3)

Paralysis (Phase 3)

Parkinson Disease (Phase 4)

Pneumonia (Phase 1)

Pneumonia, Ventilator-Associated (Phase 1)

Prostatic Neoplasms (Phase 3)

Psoriasis (Phase 2)

Pulmonary Aspergillosis (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Retinal Diseases (Phase 2)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Subarachnoid Hemorrhage (Phase 3)

Surgical Wound Infection (Phase 4)

Syndrome (Phase 3)

Tourette Syndrome (Phase 2)

Vocal Cord Paralysis (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 79
  • # of Trial APIs: 112